• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

HPV E5 通过 EGFR 信号对病毒生命周期的影响。

Impact of HPV E5 on viral life cycle via EGFR signaling.

机构信息

Atta-Ur-Rahman School of Applied Biosciences, National University of Science and Technology, H-12 Campus, Islamabad, Pakistan.

出版信息

Microb Pathog. 2020 Feb;139:103923. doi: 10.1016/j.micpath.2019.103923. Epub 2019 Dec 11.

DOI:10.1016/j.micpath.2019.103923
PMID:31836496
Abstract

Oncoprotein E5 is gaining popularity with time as the third transforming protein of Human Papillomavirus (HPV). Extensive proliferation is the distinguished feature of developing cancers, and E5 is able to stimulate keratinocytes proliferation via upregulation of EGFR signaling pathway. Thus E5 is thought to indirectly contribute to the completion of the viral life-cycle by generating the adequate cellular environment. By amplifying EGFR signaling E5 delays differentiation and allows hyperproliferation of keratinocytes which otherwise would have followed a normal differentiation pathway. Thus exploring the mechanisms by which HPV E5 regulates signaling by EGFR receptors in detail suggest new ways of inhibiting HPV-mediated disease progression.

摘要

癌蛋白 E5 随着时间的推移逐渐受到关注,成为人乳头瘤病毒 (HPV) 的第三种转化蛋白。广泛增殖是癌症发展的显著特征,E5 能够通过上调 EGFR 信号通路刺激角质形成细胞增殖。因此,E5 被认为通过产生足够的细胞环境间接促进病毒生命周期的完成。通过放大 EGFR 信号,E5 延迟角质形成细胞的分化,并允许其过度增殖,否则这些细胞将遵循正常的分化途径。因此,详细研究 HPV E5 如何调节 EGFR 受体信号转导的机制,为抑制 HPV 介导的疾病进展提供了新的途径。

相似文献

1
Impact of HPV E5 on viral life cycle via EGFR signaling.HPV E5 通过 EGFR 信号对病毒生命周期的影响。
Microb Pathog. 2020 Feb;139:103923. doi: 10.1016/j.micpath.2019.103923. Epub 2019 Dec 11.
2
The E5 oncoprotein of human papillomavirus type 16 transforms fibroblasts and effects the downregulation of the epidermal growth factor receptor in keratinocytes.人乳头瘤病毒16型的E5癌蛋白可转化成纤维细胞,并影响角质形成细胞中表皮生长因子受体的下调。
J Virol. 1993 Aug;67(8):4521-32. doi: 10.1128/JVI.67.8.4521-4532.1993.
3
Human Papillomavirus 16 E5 Inhibits Interferon Signaling and Supports Episomal Viral Maintenance.人乳头瘤病毒 16 E5 抑制干扰素信号通路并支持病毒的游离维持。
J Virol. 2020 Jan 6;94(2). doi: 10.1128/JVI.01582-19.
4
Quantitative role of the human papillomavirus type 16 E5 gene during the productive stage of the viral life cycle.人乳头瘤病毒16型E5基因在病毒生命周期增殖阶段的定量作用。
J Virol. 2003 Mar;77(5):2832-42. doi: 10.1128/jvi.77.5.2832-2842.2003.
5
Novel Functions of the Human Papillomavirus E6 Oncoproteins.人乳头瘤病毒 E6 癌蛋白的新功能。
Annu Rev Virol. 2015 Nov;2(1):403-23. doi: 10.1146/annurev-virology-100114-055021. Epub 2015 Sep 2.
6
Epidermal growth factor receptor-dependent stimulation of differentiation by human papillomavirus type 16 E5.人乳头瘤病毒 16 型 E5 通过表皮生长因子受体依赖性刺激分化。
Virology. 2024 Feb;590:109952. doi: 10.1016/j.virol.2023.109952. Epub 2023 Dec 12.
7
Human papillomavirus E5 oncoproteins bind the A4 endoplasmic reticulum protein to regulate proliferative ability upon differentiation.人乳头瘤病毒 E5 癌蛋白结合 A4 内质网蛋白以调节分化时的增殖能力。
Virology. 2014 Mar;452-453:223-30. doi: 10.1016/j.virol.2014.01.013. Epub 2014 Feb 14.
8
Signaling pathways in HPV-associated cancers and therapeutic implications.HPV 相关癌症中的信号通路及治疗意义。
Rev Med Virol. 2015 Mar;25 Suppl 1:24-53. doi: 10.1002/rmv.1823.
9
The E5 oncoprotein of human papillomavirus type 16 inhibits the acidification of endosomes in human keratinocytes.人乳头瘤病毒16型的E5癌蛋白可抑制人角质形成细胞中内体的酸化。
J Virol. 1995 May;69(5):3185-92. doi: 10.1128/JVI.69.5.3185-3192.1995.
10
The HPV-16 E5 protein represses expression of stress pathway genes XBP-1 and COX-2 in genital keratinocytes.HPV-16 E5 蛋白抑制生殖器角质形成细胞中应激途径基因 XBP-1 和 COX-2 的表达。
Biochem Biophys Res Commun. 2010 Sep 3;399(4):617-22. doi: 10.1016/j.bbrc.2010.07.125. Epub 2010 Aug 3.

引用本文的文献

1
Genome integration of human DNA oncoviruses.人类DNA肿瘤病毒的基因组整合
J Virol. 2025 Aug 19;99(8):e0056225. doi: 10.1128/jvi.00562-25. Epub 2025 Jul 23.
2
Viral oncogenesis in cancer: from mechanisms to therapeutics.癌症中的病毒致癌作用:从机制到治疗
Signal Transduct Target Ther. 2025 May 12;10(1):151. doi: 10.1038/s41392-025-02197-9.
3
Human papilloma virus (HPV) mediated cancers: an insightful update.人乳头瘤病毒(HPV)介导的癌症:深入的最新进展
J Transl Med. 2025 Apr 29;23(1):483. doi: 10.1186/s12967-025-06470-x.
4
E5 Oncoprotein: A Key Player in Human Papillomavirus-Positive Head and Neck Cancer Pathogenesis and Therapy Resistance.E5癌蛋白:人乳头瘤病毒阳性头颈癌发病机制和治疗抵抗中的关键因素
Viruses. 2025 Apr 1;17(4):512. doi: 10.3390/v17040512.
5
Regulation of epithelial growth factor receptors by the oncoprotein E5 during the HPV16 differentiation-dependent life cycle.人乳头瘤病毒16型分化依赖性生活周期中癌蛋白E5对上皮生长因子受体的调控
Tumour Virus Res. 2025 Mar 7;19:200315. doi: 10.1016/j.tvr.2025.200315.
6
Exploring the metabolic alterations in cervical cancer induced by HPV oncoproteins: From mechanisms to therapeutic targets.探索人乳头瘤病毒癌蛋白诱导的宫颈癌代谢改变:从机制到治疗靶点
Biochim Biophys Acta Rev Cancer. 2025 Apr;1880(2):189292. doi: 10.1016/j.bbcan.2025.189292. Epub 2025 Mar 2.
7
Roles of human papillomavirus in cancers: oncogenic mechanisms and clinical use.人乳头瘤病毒在癌症中的作用:致癌机制与临床应用
Signal Transduct Target Ther. 2025 Jan 24;10(1):44. doi: 10.1038/s41392-024-02083-w.
8
Viral Oncogenesis: Synergistic Role of Genome Integration and Persistence.病毒致癌作用:基因组整合与持续性的协同作用
Viruses. 2024 Dec 23;16(12):1965. doi: 10.3390/v16121965.
9
Identification of proteins' expression pathway and the effective miRNAs for the treatment of human papillomavirus-induced cervical cancer: in-silico analyses-experimental research.鉴定蛋白质表达途径及用于治疗人乳头瘤病毒诱导的宫颈癌的有效微小RNA:计算机模拟分析-实验研究
Ann Med Surg (Lond). 2024 Aug 30;86(10):5784-5792. doi: 10.1097/MS9.0000000000002513. eCollection 2024 Oct.
10
Immunoinformatics Design and In Vivo Immunogenicity Evaluation of a Conserved CTL Multi-Epitope Vaccine Targeting HPV16 E5, E6, and E7 Proteins.针对人乳头瘤病毒16型E5、E6和E7蛋白的保守细胞毒性T淋巴细胞多表位疫苗的免疫信息学设计及体内免疫原性评估
Vaccines (Basel). 2024 Apr 9;12(4):392. doi: 10.3390/vaccines12040392.